- Home
- ALAR vs SKYE Comparison
ALAR vs SKYE Comparison
Compare ALAR & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALAR
- SKYE
- Stock Information
- Founded
- ALAR 2013
- SKYE 2012
- Country
- ALAR Israel
- SKYE United States
- Employees
- ALAR N/A
- SKYE N/A
- Industry
- ALAR Computer Software: Prepackaged Software
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- ALAR Technology
- SKYE Health Care
- Exchange
- ALAR Nasdaq
- SKYE Nasdaq
- Market Cap
- ALAR 105.3M
- SKYE 121.8M
- IPO Year
- ALAR 2018
- SKYE N/A
- Fundamental
- Price
- ALAR $15.32
- SKYE $1.51
- Analyst Decision
- ALAR Strong Buy
- SKYE Strong Buy
- Analyst Count
- ALAR 1
- SKYE 5
- Target Price
- ALAR $27.00
- SKYE $14.75
- AVG Volume (30 Days)
- ALAR 61.8K
- SKYE 1.7M
- Earning Date
- ALAR 11-24-2025
- SKYE 11-06-2025
- Dividend Yield
- ALAR N/A
- SKYE N/A
- EPS Growth
- ALAR N/A
- SKYE N/A
- EPS
- ALAR 0.07
- SKYE N/A
- Revenue
- ALAR $30,488,000.00
- SKYE N/A
- Revenue This Year
- ALAR $28.77
- SKYE N/A
- Revenue Next Year
- ALAR $31.83
- SKYE N/A
- P/E Ratio
- ALAR $18.51
- SKYE N/A
- Revenue Growth
- ALAR N/A
- SKYE N/A
- 52 Week Low
- ALAR $5.45
- SKYE $1.14
- 52 Week High
- ALAR $21.50
- SKYE $5.96
- Technical
- Relative Strength Index (RSI)
- ALAR 52.02
- SKYE 28.46
- Support Level
- ALAR $13.72
- SKYE $1.78
- Resistance Level
- ALAR $15.74
- SKYE $1.76
- Average True Range (ATR)
- ALAR 0.73
- SKYE 0.32
- MACD
- ALAR -0.08
- SKYE -0.28
- Stochastic Oscillator
- ALAR 61.42
- SKYE 0.40
About ALAR Alarum Technologies Ltd.
Alarum Technologies Ltd is a software-as-a-service (SaaS) provider operating mainly in the web data collection market, offering web data collection and a private internet browsing platform. The company's Web Data Collection products offer secure, fast, and anonymous IP Proxy Network Solutions & Services, or IPPN or IPPN Solutions, to its business customers which, in turn, enables them to anonymously and securely browse the internet as well as to collect data from any publicly available source on the web, for their business purpose. The company operates in one segment, which is web data collection. Geographically, it derives maximum revenue from United Arab Emirates, followed by China, the United States, Europe, Asia-Pacific, U.K. Virgin Islands, Middle East and Africa, and other regions.
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.